Stryker said reported net sales for Q3 2024 rose 11.9% to $5.5 billion, and organic net sales rose 11.5%. The company attributed 10.3% of the organic growth to higher unit volume and 1.2% to higher prices.

1. 01

   Stryker said reported net sales for Q3 2024 rose 11.9% to $5.5 billion, and organic net sales rose 11.5%. The company attributed 10.3% of the organic growth to higher unit volume and 1.2% to higher prices.

2. 02

   The company said reported net earnings for Q3 were $834 million, up 20.5%, and reported diluted earnings per share were $2.16. It said adjusted operating income margin was 24.7% and adjusted diluted earnings per share were $2.87.

3. 03

   Stryker said it expects full-year 2024 organic net sales growth of 9.5% to 10.0% and adjusted diluted earnings per share of $12.00 to $12.10. The company said that if foreign exchange rates hold near current levels, adjusted diluted earnings per share would be negatively impacted by approximately $0.10.

4. 04

   Stryker reported net cash provided by operating activities of $2,311 million for the 9 months ended 2024, and spent $1,598 million on acquisitions, net of cash acquired. Over the same period, net borrowings of debt were $2,378 million, and dividend payments were $914 million.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.